While we are familiar with the Propionate ester the remaining three esters that create Sustanon-250 are almost always found as part of a mixture or compounded anabolic androgenic steroid .
Developed by Organon, the original idea behind Sustanon-250 was to provide a testosterone form well-suited for hormone replacement therapy that would only needed to be administered once every few weeks and for all intense purposes the idea was a success. For the performance enhancing athlete Sustanon-250 can be a fine choice but the idea of injecting only once or twice a month is not applicable here. As a performance enhancer this testosterone like all forms will need to be administered on a more frequent basis. This mixture carries with it two fast, short esters, Propionate and Pheylpropionate, a longer more moderate ester Isocaproate and the very slow and long Decanoate ester. In order to keep testosterone levels stable and at their peak most athletes will inject Sustanon-250 at a minimum of every 3 days and more commonly every other day for optimal results.
For more info see: Sustanon-250
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) medication guide for Testosterone. For Testosterone Undecanoate, REMS includes elements to assure safe use and implementation system . For additional information: /REMS
US BOXED WARNINGS :
Pulmonary Oil Microembolism (POME) Reactions And Anaphylaxis :
-Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.
-Following each injection of testosterone undecanoate observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.
Secondary Exposure To Topical Testosterone :
-Virilization has been reported in children who were secondarily exposed to topical testosterone products.
-Children should avoid contact with unwashed or unclothed application sites in men using testosterone topical.
-Healthcare providers should advise patients to strictly adhere to recommended instructions for use.
Safety and efficacy have not been established in patients younger than 18 years.
Testosterone Enanthate and Testosterone Implant are indicated for delayed puberty in adolescent patients.
Testosterone Cypionate: Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.